CRVO

In May 2026, CervoMed reported its first-quarter financial results, provided corporate updates, and presented new MRI data at AAN 2026, highlighting reversible disease progression with neflamapimod. In June 2026, the company completed two equity financings, raising approximately $20.5 million, which extended its cash runway through Q3 2027, and received a U.S. patent allowance for neflamapimod in DLB. In July 2026, CervoMed announced new clinical, plasma biomarker, and imaging data for neflamapimod in DLB at AAIC 2026. In August 2026, the company reported its second-quarter financial results, emphasized securing a partnership for neflamapimod's Phase 3 trial, and received an Innovation Passport Designation under the UK's ILAP for DLB. In September 2026, CervoMed announced pharmacokinetic results with a new neflamapimod oral tablet formulation, secured FDA removal of a drug exposure limit, and had initial Phase 2a nfvPPA trial results accepted for presentation. Overall, the stock price has experienced significant volatility, with a rise of 8.78% in the past week and 27.27% in the past month, but a decrease of 20.10% over the last six months and 64.65% over the last year.